17:00 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Sutro raises $85.4M series E

Sutro Biopharma Inc. (South San Francisco, Calif.) raised $85.4 million on July 26 in an untranched series E round led by new investors Samsara BioCapital and Surveyor Capital. Also participating in the round were existing investors...
23:40 , Jul 26, 2018 |  BC Extra  |  Financial News

Sutro raises $85.4M series E

Sutro Biopharma Inc. (South San Francisco, Calif.) raised $85.4 million in an untranched series E round led by new investors Samsara BioCapital and Surveyor Capital. Also participating in the round were existing investors Alta Partners, Amgen...
19:59 , Jun 15, 2018 |  BC Week In Review  |  Financial News

After announced merger, TapImmune raises $70M

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 June 8 after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors...
19:14 , Jun 8, 2018 |  BC Extra  |  Financial News

TapImmune shares climb on $70M offering

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 Friday after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors Aisling...
15:16 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through the...
14:05 , Jun 7, 2018 |  BC Extra  |  Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through the...
18:53 , Jun 1, 2018 |  BC Week In Review  |  Company News

TapImmune, Marker Therapeutics merge

TapImmune (NASDAQ:TPIV) will merge with Marker Therapeutics Inc. (New Brighton, Minn.) to create a new cell therapy company. The merged company will use Marker Therapeutics's multi-antigen targeted cell therapy platform with TapImmune's peptide vaccine portfolio....
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

ImmunoGen reports updated Phase Ib/II data for ovarian cancer candidate

ImmunoGen Inc. (NASDAQ:IMGN) reported updated data from the Phase Ib/II FORWARD II trial evaluating mirvetuximab soravtansine (IMGN853) to treat folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer. The data were released in an abstract...
18:32 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A click chemistry-based method for identifying cell surface glycoproteins that bind orphan ligands could help identify new therapeutic targets. The method involves three steps: mildly oxidizing live cells to produce aldehyde...
17:30 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

ImmunoGen reports Phase Ib/II data for mirvetuximab soravtansine plus Keytruda in ovarian cancer

ImmunoGen Inc. (NASDAQ:IMGN) reported data from 14 evaluable heavily pretreated folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer patients in the dose-escalation portion of the Phase Ib/II FORWARD II trial showing that mirvetuximab soravtansine...